Study guide
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD)
EBP-EAP Examination in Paediatrics Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding
EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)
2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity
Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol
3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections
Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening
4 Chapter 4: Acute Paediatric Emergencies & Critical Care
EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination
5 Chapter 5: Paediatric Respiratory Medicine
Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations
6 Chapter 6: Paediatric Cardiology
Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever
7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition
Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure
8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance
Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management
9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)
10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy
11 Chapter 11: Paediatric Haematology & Oncology
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia
12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy
Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules
13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions
The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia
14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics
15 Chapter 15: Paediatric Ophthalmology & ENT Disorders
Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions
16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health
Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance
17 Chapter 17: Adolescent Medicine & Healthcare Transition
Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition
18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics
Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics
19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine
Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD)
Key Takeaways Explain This Topic AI
Term neonates experience a physiological hemoglobin nadir of 90–110 g/L between 8 and 12 weeks of age due to abrupt post-natal downregulation of erythropoietin synthesis following room-air oxygenation.
The Mentzer Index (MCV / RBC count) is a screening clue: >13 favors iron deficiency and <13 favors beta-thalassaemia trait. Confirm iron status and haemoglobin analysis; thalassaemia trait does not exclude coexisting iron deficiency.
Excessive unfortified cow's milk (>500 mL/day) is the leading dietary trigger of toddler iron deficiency anaemia; oral elemental iron (3–6 mg/kg/day) must be continued for 3 months after normalisation of haemoglobin to replenish reticuloendothelial stores.
Hereditary spherocytosis causes extravascular splenic hemolysis from red cell membrane defects. EMA flow cytometry supports diagnosis; folate is used in moderate/severe disease and splenectomy is selected by severity, usually deferred until at least age 6.
G6PD deficiency is an X-linked enzymopathy where acute oxidative stress triggers intravascular and extravascular hemolysis with bite cells and Heinz bodies; quantitative enzyme assays can be falsely normal during acute crisis and require repeat testing 2–3 months later.
Last updated: November 2026
Pediatric Anemias: Age-Adjusted Norms, Microcytic Differentials, and Congenital Hemolytic Disorders
Anemia is one of the most frequent clinical presentations encountered in general and hospital pediatrics. Because childhood hematology is defined by dynamic developmental changes from the neonatal period through adolescence, the clinical approach to pediatric anemia requires anchoring laboratory values to age-specific reference intervals. Understanding the pathophysiological mechanisms governing red cell production, membrane integrity, and hemoglobin synthesis is essential for solving clinical vignettes on the European Board of Paediatrics (EBP-EAP) examination.
Age-Dependent Hemoglobin Norms and the Physiological Nadir
At birth, full-term infants possess elevated hemoglobin concentrations ( 140 to 200 g/L ) with macrocytic indices (mean corpuscular volume [MCV] 100 to 120 fL ). Fetal hemoglobin ( HbF , α₂γ₂) comprises 60% to 80% of circulating hemoglobin, facilitating transplacental oxygen uptake due to its high oxygen affinity (shifted left on the oxygen-hemoglobin dissociation curve).
The Postnatal Transition and Physiological Nadir
Delivery and the initiation of spontaneous ventilation trigger profound changes in oxygen kinetics:
Downregulation of Erythropoietin (EPO): After birth, lung aeration and increased arterial oxygenation improve tissue oxygen delivery. This reduces the stimulus for erythropoietin production, so circulating EPO concentrations fall and erythropoiesis is temporarily suppressed. Combined with shorter neonatal red-cell survival, this produces the physiological fall in hemoglobin.
The Physiological Nadir of Infancy: With erythropoiesis temporarily suppressed and red blood cell lifespan shortened in neonates (60–90 days versus 120 days in adults), hemoglobin progressively declines, reaching a physiological nadir between 8 and 12 weeks of age in healthy term infants, with hemoglobin dipping to 90 to 110 g/L (9.0–11.0 g/dL). Erythrocytes remain normocytic and normochromic, and reticulocyte counts drop transiently.
Rebound Erythropoiesis: As somatic growth continues and tissue metabolic demand rises, tissue hypoxia stimulates renewed renal EPO secretion around 3 to 4 months of age, driving reticulocytosis and normalizing hemoglobin levels.
Anemia of Prematurity: In preterm infants (<37 weeks gestation, particularly very low birth weight [<1500 g] neonates), the physiological nadir occurs earlier (at 4 to 8 weeks ), reaches a significantly deeper nadir (hemoglobin frequently falling below 70 to 80 g/L ), and is exacerbated by diminished initial red cell mass, truncated placental iron transfer, shorter red cell survival (40–60 days), and frequent iatrogenic phlebotomy losses.
Note
Transplacental iron transfer occurs predominantly during the third trimester of gestation. Consequently, healthy full-term infants are born with sufficient endogenous reticuloendothelial iron stores to sustain somatic growth and hemoglobin synthesis until 4 to 6 months of age . Preterm infants exhaust their diminished iron reserves significantly earlier (by 2 to 3 months of life ), necessitating routine iron supplementation starting at 2 to 4 weeks of chronological age.
Algorithmic Approach to Childhood Anemias by Mean Corpuscular Volume (MCV)
Pediatric anemias are systematically categorized by mean corpuscular volume (MCV) into microcytic , normocytic , and macrocytic categories. Because adult MCV thresholds cannot be applied to children, pediatric clinicians evaluate MCV against age-adjusted reference ranges, using the approximation Lower Limit of Normal MCV (fL) = 70 + age in years for ages 1–10 years; use laboratory age-specific ranges outside this interval. [Pediatric Anemia Workup]
- |
- +-----------------------+-----------------------+
- | | |
- [Microcytic (Low MCV)] [Normocytic (Normal MCV)] [Macrocytic (High MCV)]
- Iron Deficiency - Acute Blood Loss - B12 / Folate Deficiency
- Beta-Thalassemia Trait - Hemolysis (immune/membr.) - Hypothyroidism
- Alpha-Thalassemia Trait- Anemia of Chronic Dis. - Fanconi Anemia
- Lead Poisoning - Transient Erythroblast. - Diamond-Blackfan Anemia
- Sideroblastic Anemia of Childhood (TEC) - Bone Marrow Failure
- Normocytic and Macrocytic Differentials of High Clinical Yield
Transient Erythroblastopenia of Childhood (TEC): A self-limiting, acquired pure red cell aplasia occurring between 1 and 4 years of age , often following an uncharacterized viral infection. Patients present with severe, insidious normocytic anemia (Hb 40–80 g/L) with profound reticulocytopenia (<0.1%) , normal white blood cells and platelets, and absent physical anomalies. Bone marrow recovers spontaneously within 4 to 8 weeks; red cell adenosine deaminase (eADA) is characteristically normal (differentiating TEC from congenital red cell aplasias).
Diamond-Blackfan Anemia (DBA): A rare congenital pure red cell aplasia manifesting within the first year of life (usually by 2–3 months). Features include macrocytic anemia, reticulocytopenia, elevated erythrocyte adenosine deaminase (eADA) , and characteristic physical anomalies in 50% of patients: triphalangeal or hypoplastic thumbs, craniofacial dysmorphism (hypertelorism, micrognathia), short stature, and webbed neck. Managed with corticosteroids and chronic transfusions.
Fanconi Anemia (FA): The most common inherited bone marrow failure syndrome, inherited primarily in an autosomal recessive pattern involving defective DNA repair complexes. It typically presents between 5 and 10 years of age with progressive macrocytic anemia that evolves into fatal aplastic pancytopenia. Hallmark physical signs include café-au-lait macules , hypopigmented patches, absent or hypoplastic thumbs and radius , short stature, microcephaly, and renal or structural urinary tract anomalies. Diagnosis is confirmed by demonstrating chromosomal breakage following exposure of peripheral blood lymphocytes to DNA cross-linking agents (diepoxybutane [DEB] or mitomycin C [MMC]).
Microcytic Hypochromic Anemias: Iron Deficiency vs Beta-Thalassaemia Trait
The vast majority of pediatric microcytic anemias represent either Iron Deficiency Anemia (IDA) or Beta-Thalassaemia Trait (Minor) . Rapidly differentiating these conditions avoids unnecessary invasive testing or inappropriate, potentially toxic iron administration.
Iron Deficiency Anemia (IDA)
Epidemiology and Dietary Triggers: Iron deficiency represents the single most common nutritional disorder worldwide. In toddlers aged 12 to 36 months , excessive consumption of unmodified cow's milk ( >500 mL/day , or >16–20 oz/day) is the predominant cause. Cow's milk features low elemental iron content with poor bioavailability, induces early satiety displacing iron-dense complementary solid foods, and contains bovine calcium and casein that inhibit intestinal non-heme iron absorption. Furthermore, heat-labile bovine proteins cause subclinical intestinal mucosal inflammation resulting in occult microscopic enteric blood loss.
Laboratory Profile:
Serum Ferritin: Reflects total body reticuloendothelial iron stores. A serum ferritin <12–15 mcg/L is the most specific biochemical marker for depleted iron reserves. However, ferritin is an acute-phase reactant and can be falsely normal or elevated in concurrent systemic inflammation or infection.
Soluble Transferrin Receptor (sTfR): Elevated in iron deficiency; critically, sTfR remains elevated even in the presence of systemic inflammation, serving as an outstanding discriminating tool when ferritin is equivocal.
Red Cell Distribution Width (RDW): Markedly elevated ( RDW >15% ), reflecting prominent anisocytosis (variation in erythrocyte size) as newly produced microcytes mix with older normocytic erythrocytes.
Total Iron-Binding Capacity (TIBC): Elevated, with a low transferrin saturation ( <15% ).
Pharmacological Treatment of IDA:
Dosing: Oral elemental iron at 3 to 6 mg/kg/day (administered as ferrous sulfate, ferrous fumarate, or ferrous gluconate) divided once or twice daily.
Optimization: Administered between meals or with ascorbic acid (Vitamin C, e.g., fresh orange juice) to promote reduction of ferric (Fe³⁺) to absorbable ferrous (Fe²⁺) iron. Co-ingestion with dairy milk, tea, or antacids must be strictly avoided.
Duration of Therapy: Iron therapy must be continued for at least 3 months after normalization of hemoglobin to completely replenish exhausted reticuloendothelial bone marrow ferritin stores.
Expected Response: Reticulocytosis peaks at 5 to 7 days , followed by an increase in hemoglobin of at least 10 g/L within 3 to 4 weeks .
Dietary Modification: Limit whole cow's milk to less than 500 mL/day and introduce iron-fortified cereals, pulses, and heme-rich meats.
Beta-Thalassaemia Trait (Minor)
Pathophysiology: Caused by heterozygous point mutations or deletions in the beta-globin gene ( HBB on chromosome 11), leading to reduced (β⁺) or absent (β⁰) synthesis of beta-globin chains. Because alpha-globin chains are produced in normal quantities, relative alpha-chain excess causes mild, ineffective erythropoiesis, but the marrow compensates with robust erythroid hyperplasia.
Laboratory Profile: Characterized by a mild microcytic hypochromic anemia (hemoglobin typically 95–115 g/L) with disproportionately profound microcytosis (MCV typically 55 to 70 fL , often far lower than seen in an equivalent degree of iron deficiency). Total red blood cell count is physiologically elevated ( RBC count >5.0 to 5.5 × 10¹²/L ). RDW remains uniform and normal ( RDW <14% ). Serum ferritin and iron studies are normal in isolated trait; coexisting iron deficiency must be assessed separately.
Diagnostic Confirmation: Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) reveals elevated Hemoglobin A2 (HbA2 >3.5%) and occasionally slightly elevated HbF (1–3%) .
The Mentzer Index
The Mentzer Index is a validated, rapid screening calculation utilizing routine complete blood count parameters to differentiate iron deficiency from beta-thalassemia trait: Mentzer Index = MCV (fL) RBC Count ( 10 12 /L ) \text{Mentzer Index} = \frac{\text{MCV (fL)}}{\text{RBC Count } (10^{12}\text{/L})} Mentzer Index = RBC Count ( 1 0 12 /L ) MCV (fL)
Mentzer Index > 13: Strongly indicates Iron Deficiency Anemia . In IDA, both iron deficiency and diminished red cell production drive MCV down, but the red blood cell count drops substantially, yielding a higher ratio.
Mentzer Index < 13: Strongly indicates Beta-Thalassaemia Trait . In thalassaemia trait, red cell production remains intense (producing a high RBC count) while individual cells are extremely microcytic, generating a low ratio.
- Parameter Iron Deficiency Anemia (IDA) Beta-Thalassaemia Trait Anemia of Chronic Disease
- Hemoglobin Low (variable severity) Mildly reduced (95–115 g/L) Mildly reduced (85–110 g/L)
- MCV Low (correlates with severity) Markedly low (often <70 fL) Normal to slightly low
- RBC Count Decreased (<4.5 × 10¹²/L) Normal or Elevated (>5.0 × 10¹²/L) Normal or decreased
- Mentzer Index > 13 < 13 Variable (often >13)
- RDW Elevated (>15%) Normal (<14%) Normal to mildly elevated
- Serum Ferritin Low (<12–15 mcg/L) Normal Normal to Elevated (acute phase)
- Transferrin Saturation Low (<15%) Normal Low to normal
- Hemoglobin A2 Within the laboratory range or decreased Elevated (>3.5%) Normal
Peripheral Smear Hypochromia, pencil/cigar cells Microcytes, target cells, basophilic stippling Normocytic, normochromic
Warning
Iron does not treat thalassaemia trait itself. Check for coexisting iron deficiency and treat it when demonstrated; a Mentzer Index <13 or elevated HbA2 does not prohibit iron. Normal ferritin may mask deficiency during inflammation. Use iron studies in clinical context and offer carrier counseling.
Congenital Hemolytic Anemias
Hemolytic anemias are characterized by premature red blood cell destruction (lifespan <120 days). The classic clinical triad comprises pallor , unconjugated hyperbilirubinemic jaundice , and splenomegaly . Laboratory hallmarks of active hemolysis include elevated reticulocytes (>2–3%), elevated serum lactate dehydrogenase (LDH), reduced or undetectable haptoglobin, and hemoglobinuria/hemosiderinuria in intravascular hemolysis.
Hereditary Spherocytosis (HS)
Genetics and Cytoskeleton Pathology: Hereditary spherocytosis is the most common inherited hemolytic anemia in Northern European populations (prevalence ~1 in 2,000). It is inherited in an autosomal dominant pattern in 75% of cases (with 25% representing de novo mutations or recessive inheritance). The underlying molecular defect involves abnormalities in red cell membrane cytoskeletal proteins:
- Ankyrin ( ANK1 ) : Most frequent defect (50%)
- Band 3 ( SLC4A1 ) : ~20%
- Beta-Spectrin ( SPTB ) and Protein 4.2 ( EPB42 )
Pathogenesis: Disruption of vertical linkages between the lipid bilayer and the spectrin cytoskeleton causes progressive loss of membrane surface area via microvesiculation without proportional loss of intracellular volume. Erythrocytes lose their flexible biconcave disk architecture and transform into rigid, spherical cells ( spherocytes ) with diminished deformability. As spherocytes pass through the tortuous, acidic, and hypoxic cords of Billroth in the spleen, they cannot traverse the narrow endothelial slits into the sinusoids. Splenic macrophages phagocytose the entrapped spherocytes, resulting in chronic extravascular hemolysis .
Clinical Presentation:
Neonatal period: Pathological unconjugated hyperbilirubinemia often requiring intensive phototherapy or exchange transfusion.
Childhood: Chronic compensated or uncompensated hemolytic anemia, fluctuating mild scleral icterus, and progressive splenomegaly.
Pigment Gallstones (Cholelithiasis): Chronic bilirubin hypersecretion leads to calcium bilirubinate gallstones in up to 50% of untreated adolescents.
Aplastic Crisis: Triggered by Parvovirus B19 infection. Parvovirus B19 selectively infects and arrests erythroblast progenitors in the bone marrow. In a child with baseline red cell survival of only 15 to 20 days, temporary cessation of erythropoiesis causes an abrupt, life-threatening drop in hemoglobin accompanied by reticulocytopenia (<0.1%) .
Diagnostic Evaluation:
Peripheral blood film: Abundant small, round, hyperchromic microspherocytes lacking central pallor, accompanied by polychromasia.
Indices: Mean Corpuscular Hemoglobin Concentration is characteristically elevated ( MCHC >350 to 360 g/L ) due to cellular dehydration.
Direct Antiglobulin Test (DAT / Direct Coombs): Characteristically negative , distinguishing HS from autoimmune hemolytic anemia (AIHA).
Flow Cytometry (EMA Binding Test): The Eosin-5-maleimide (EMA) binding test is a recommended first-line screening test when the diagnosis is uncertain. EMA binds to Band 3 and associated membrane complexes; HS red cells show reduced mean fluorescence intensity. Interpret the result with the family history, blood film and indices. Cryohaemolysis is another recommended screen; osmotic fragility is not recommended for routine screening.
Management:
Folic Acid Supplementation: Daily oral folic acid (e.g., 1 mg/day) is recommended in moderate or severe HS; routine supplementation is unnecessary in mild disease.
Splenectomy Indications and Rules: Splenectomy is recommended for severe HS, considered for symptomatic moderate disease, and usually unnecessary for mild disease. It reduces hemolysis and anemia but leaves the membrane defect and spherocytes. Because Overwhelming Post-Splenectomy Infection (OPSI) , particularly pneumococcal infection, remains a lifelong risk, elective surgery is preferably deferred until at least 6 years of age .
Pre- and Post-Splenectomy Prophylaxis: Complete pneumococcal, meningococcal and indicated Hib vaccination according to age, previous doses and current national asplenia schedules, ideally at least 2 weeks before elective surgery . Give daily Penicillin V prophylaxis after splenectomy; duration depends on age, time since surgery and continuing risk, with lifelong treatment for high-risk patients. Fever requires urgent assessment and parenteral antibiotics.
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
Genetics and Enzymology: G6PD deficiency is the most common enzymatic red cell disorder, affecting over 400 million individuals globally. It is an X-linked recessive condition ( G6PD gene on chromosome Xq28), predominantly affecting hemizygous males (though homozygous or Lyonized heterozygous females can manifest symptoms). Important variants include G6PD Mediterranean and G6PD A- (common in African populations), historically called Classes II and III. Both fall within current WHO Class B , associated with triggered acute haemolysis and median activity <45%. This classification describes genetic variants, not individual patients.
Pathophysiology: G6PD catalyzes the conversion of glucose-6-phosphate to 6-phosphogluconolactone in the hexose monophosphate (pentose phosphate) shunt , generating NADPH . In erythrocytes—which lack mitochondria—the pentose phosphate shunt is the sole source of NADPH. NADPH is the obligate cofactor required by glutathione reductase to regenerate reduced glutathione (GSH) . GSH acts as the primary intracellular antioxidant, neutralizing hydrogen peroxide and toxic reactive oxygen species (ROS). In G6PD deficiency, oxidative stress causes uncontrolled oxidation of sulfhydryl groups on hemoglobin, causing hemoglobin denaturation and precipitation into insoluble intracellular aggregates called Heinz bodies . [Glucose-6-Phosphate] + [NADP+]
- | (G6PD enzyme)
- v
- [6-Phosphogluconolactone] + [NADPH]
- |
- v
- [Oxidized Glutathione (GSSG)] ---> [Reduced Glutathione (GSH)]
- |
- v Neutralizes H2O2 & Free Radicals
- [Protects RBC Membrane & Hb]
Oxidative Triggers:
Infections: The most common clinical trigger (viral upper respiratory infections, bacterial sepsis, hepatitis).
Dietary: Ingestion of fava beans (broad beans, Vicia faba ), containing vicine and convicine which generate toxic divicine and isouramil (favism).
Medications: High-risk drugs include standard daily primaquine , tafenoquine, dapsone and rasburicase . Nitrofurantoin requires caution and monitoring; sulfamethoxazole has low-to-no haemolytic risk at standard doses under CPIC guidance.
Chemicals: Ingestion or inhalation of naphthalene ( mothballs ).
Clinical Presentation: Typically asymptomatic between episodes. Following oxidative exposure (usually 24 to 72 hours later), patients develop acute, explosive hemolysis featuring both intravascular and extravascular red cell destruction. Symptoms include sudden pallor, jaundice, abdominal or lumbar back pain, and passing dark, reddish-brown "Coca-Cola" or port-wine colored urine (hemoglobinuria).
Diagnostic Workup:
Peripheral Blood Film: Supravital staining (new methylene blue or crystal violet) reveals Heinz bodies . Standard Wright-Giemsa staining demonstrates "bite cells" (degmacytes: red cells where splenic macrophages have pitted out rigid Heinz body precipitates) and "blister cells" (eccentrocytes: red cells where oxidized hemoglobin has contracted away from the cell membrane).
Urinalysis: Positive for blood on dipstick (due to free hemoglobin) with an absence of intact red blood cells on microscopic sediment examination.
Diagnostic Caveat (The Reticulocyte Trap): During an acute hemolytic crisis, the oldest erythrocytes—possessing the lowest residual G6PD enzyme levels—are selectively hemolyzed first. The bone marrow responds with robust reticulocytosis. Because young reticulocytes and newly minted red cells have normal or elevated G6PD enzyme activity, a quantitative spectrophotometric G6PD enzyme assay performed during or immediately following an acute hemolytic episode can be falsely normal . Definitive enzymatic assay must be scheduled 2 to 3 months after the acute episode has completely resolved and reticulocytosis has subsided.
Management: Primary therapy is prevention : provide families with advice on avoiding fava beans and high-risk oxidant drugs, and checking new medicines. During an acute hemolytic crisis, immediately discontinue any inciting pharmaceutical agent, maintain adequate hydration, using IV fluids when needed and monitoring urine output, renal function and fluid balance, and administer packed red blood cell transfusions for severe, symptomatic anemia.